CWRU medical research study says President Biden’s COVID-19 rebound not unique to Paxlovid
The Plain Dealer: Pamela Davis, the Arline H. and Curtis F. Garvin Research Professor at the School of Medicine, discussed her recent research showing that COVID-19 rebound occurred in about 5% of patients 30 days after treatment with Paxlovid and in approximately 8% of patients 30 days after treatment with Molnupiravir. “Our studies comparing rebound from Paxlovid and Molnupiravir showed that rebound occurs from both drugs but to a greater extent with Molnupiravir,” she said.